Evaluation of Circulating Tumor DNA as a Biomarker for Chemoresistance in Colorectal Cancer

Koduvayur Roopa Lakshmi, Charan Sankar Sankaranarayanan, Raja A. S. Gogineni, K. Afsar Shaheen, Parasharan Peddi · 2025

Read Evaluation of Circulating Tumor DNA as a Biomarker for Chemoresistance in Colorectal Cancer by Koduvayur Roopa Lakshmi, Charan Sankar Sankaranarayanan, Raja A. S. Gogineni, K. Afsar Shaheen, Parasharan Peddi (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12788532.txt.

Description

Koduvayur Roopa Lakshmi and co-authors present a biomarker study, published in 2025, on reading tumor DNA in the blood to foresee chemotherapy failure in bowel cancer. Ninety-six patients with stage two to four disease began the standard FOLFOX regimen while the team sampled their blood before treatment and after the third and sixth cycles. Just over a third proved resistant to the drugs.

Resistant patients started with markedly more tumor DNA in their blood, and mutations in the TP53 gene were twice as common among them. A clear drop in tumor DNA by the third cycle flagged the responders well. The authors propose blood based monitoring as an early warning that a regimen is failing, months before scans confess it.

Catalog record

CREATORKoduvayur Roopa Lakshmi, Charan Sankar Sankaranarayanan, Raja A. S. Gogineni, K. Afsar Shaheen, Parasharan Peddi
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE8 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC12788532

Browse the full library · About the Tower of Babel